Funded project
IP-NFT
ApoptoSENS - Senolytic CAR-NK Cells

ApoptoSENS - Senolytic CAR-NK Cells

Senescence
CAR-NK Cells
Ageing
Senescent cells accumulate with age and are associated with numerous diseases. Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to precisely and safely eliminate senescent cells in vivo.
Funding
$ 253,000
Initiated
25.4.2022
Approval
100% Voted Yes
Dr. Amit Sharma
Research Lead
AT A GLANCE

Stage: Early stage preclinical discovery

Area: Chimeric Antigen Receptor Natural Killer (CAR-NK) cells

Status: Ongoing

Patent: Pending

PROJECT LINKS

Background

Cellular senescence is the irreversible arrest of proliferation associated with a proinflammatory phenotype that can lead to tissue dysfunction and is implicated in numerous diseases. Natural Killer cells have an innate ability to remove senescent cells, however immune evasion can occur which contributes to an accumulation of senescent cells with age. Several genetic and pharmacological studies have shown that elimination of senescent cells can ameliorate hallmarks of aging in both mice and humans, however more specific therapeutic interventions are required.


Aims, Hypothesis & Results

Dr. Amit Sharma is developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells to precisely and safely eliminate senescent cells in vivo. The team have identified a number of senescence-specific surface markers which could be targeted for senescence removal. They will focus on their most promising candidate senescent cell markers which will be more extensively validated using additional cell model paradigms (stressors), as well as in mouse models (cross-species validation). Validated surface markers will be used to generate monoclonal antibodies, which will then be confirmed for specificity against the target antigen. Appropriate CAR-NK cells will be created to further establish proof-of-concept for their approach of selective removal of senescent cells in their various model systems.


Timeline

Pre-Clinical Studies: Monoclonal antibody generation, cloning and expression of lentiviral vectors, and CAR-NK cell generation.

Required Funding: $430,000 (VitaDAO providing $253,000)
Status: Ongoing
Duration: 24 Months

VitaDAO Board Evaluation Writeup

Dr. Amit Sharma has a strong scientific background in senescence and is based at the SENS Research Foundation which provides strong support with a track record of successful spin-outs (eg Underdog Pharma 1). The removal of senescence cells is an attractive therapeutic approach to combat aging and promote longevity. Data from Dr. Sharma’s team and others showing NK cell cytotoxicity towards senescent cells provides proof-of-concept that using CAR-NK cells is a feasible strategy to eliminate senescent cells. The team’s identification of senescence-specific cell surface markers in vitro is extremely promising and if these markers are also expressed in senescent cells in vivo, this has the potential to be an effective senolytic therapy.

Projects supported

Non Consectetur Necessitatibus

Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa

$293,00
raised
View Project

Dolorum Quia

Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex

$293,00
raised
View Project

Ex Temporibus Perferendis

Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda

$293,00
raised
View Project

Eum Harum Asperiores Id

Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin

$293,00
raised
View Project

Aperiam Et Quis Et

Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s

$293,00
raised
View Project

Culpa Possimus

Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod

$293,00
raised
View Project

Earum Est Dolorem

Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus

$293,00
raised
View Project

Voluptas Quam Sapiente

Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u

$293,00
raised
View Project

Nisi

Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l

$293,00
raised
View Project

Aut Accusantium Ut

Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita

$293,00
raised
View Project
Latest Project Updates
13
September
2022
13
September
2022
VitaDAO IP-NFT Transfer Ceremony with Molecule & ApoptoSENS

The vote has passed, the decision is made: ApoptoSENS will be the 5th research organisation to fund their longevity research via an IP-NFT.

25
April
2022
Project Initiated!

Discover more projects & initiatives

Humanity

Equity

Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.

$ 50,000
raised
View Project

Matrix Bio

IP-NFT

VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rat to human.

$ 300,000
raised
View Project

BE Therapeutics - Brain Tissue Replacement

Equity

The neocortex, the part that underlies our highest cognitive functions and self-identity, can be replaced by progressively replacing tissue areas over time without significant disruption in function or self-identity. This offers the possibility of age reversal for the neocortex through progressive tissue replacement.

$ 100,000
raised
View Project

ExcepGen Inc - RNA therapeutics for longevity

Equity

ExcepGen uses its RNAx platform to develop advanced vaccines that address viral infections linked to premature aging and shortened lifespan. The platform improves RNA cargo's effectiveness, promoting significant protein production for enhanced protection.

$ 100,000
raised
View Project

Are you working on the next longevity science breakthrough?

Apply for funding

About VitaDAO

Who can apply?
What types of projects do you fund?
What is the application structure?
Who owns IP from funded projects?
What project stages do you fund?